Effect of Orally Administrated Moxaverine on Ocular Blood Flow Clinical Trial
Official title:
A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy Subjects
A number of common eye diseases such as age-related macular degeneration and glaucoma are
associated with ocular perfusion abnormalities. Although this is well recognized there is
not much possibility to improve blood flow to the posterior pole of the eye in these
diseases.
For many years, moxaverine has been used in the therapy of perfusion abnormalities in the
brain, the heart and the extremities. This is based on a direct vasodilatatory effect of the
drug, but also on the rheological properties of red blood cells. In two recent studies the
investigators have shown that intravenous moxaverine increases choroidal and retrobulbar
blood flow in healthy young subjects, in elderly people with healthy eyes and in patients
with eye diseases associated with hypoperfusion. The present study aims to investigate,
whether ocular blood flow is also improved after oral administration of moxaverine.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science